COVID-19 vaccines shatter efficacy projections: Data Byte

With Moderna’s announcement Monday that its COVID-19 vaccine produced 94.5% protection in a Phase III trial, two mRNA vaccines have beaten their projected efficacy thresholds. The findings bode well both for other mRNA vaccines and for vaccines of other modalities that deliver the virus’ spike protein.

Release of the full Phase III protocols of leading COVID-19 vaccines made it clear the companies were aiming for at least 50% efficacy at final analysis, with higher performance needed to see statistical significance at earlier, interim analyses. ...